mTOR inhibition with temsirolimus has encouraging single-agent activity in endometrial cancer which has been shown to be more effective in chemotherapy-naive patients than in chemotherapy-treated patients and is independent of PTEN status (16). This evidence concerns the gene PTEN and endometrial cancer.